Today: 9 June 2026
Browse Category

NSE:TEJASNET 1 December 2025 - 20 January 2026

Sensex, Nifty slide to 3-month lows as ₹9.86 lakh crore evaporates — what traders are watching now

Sensex, Nifty slide to 3-month lows as ₹9.86 lakh crore evaporates — what traders are watching now

Sensex fell 1,065.71 points to close at 82,180.47, while Nifty 50 dropped 1.38% to 25,232.50, marking their lowest finishes in over three months. BSE-listed stocks lost about ₹9.86 lakh crore in market value. Over 490 NSE stocks hit 52-week lows. Analysts highlighted key Nifty support at 25,150–25,080 amid continued foreign selling.
20 January 2026
·····
Tejas Networks Share Price Today: Stock Rebounds on ₹84.95‑Crore PLI Payout After Brutal Q2 Loss

Tejas Networks Share Price Today: Stock Rebounds on ₹84.95‑Crore PLI Payout After Brutal Q2 Loss

Tejas Networks shares rose 3–4% to around ₹512 in midday trade on December 1 after the company disclosed receipt of ₹84.95 crore from the Ministry of Communications under the PLI scheme. Trading volume surged past 4 million shares, far above average. The stock remains down over 60% from last year’s highs, despite today’s rebound. Intraday, shares moved between ₹504 and ₹523 on the NSE.
1 December 2025
··

Stock Market Today

  • Designer Brands (DBI) Beats Q1 Earnings and Revenue Estimates
    June 9, 2026, 10:04 AM EDT. Designer Brands (DBI) reported Q1 earnings of $0.07 per share, surpassing the Zacks estimate of $0.02 and reversing a year-ago loss of $0.26. Revenue hit $696.35 million, just above the $696 million consensus. The company delivered a 250% earnings surprise and has beaten EPS estimates in four consecutive quarters. Shares rose about 19.5% year-to-date, outpacing the S&P 500's 8.2% gain. Despite strong results, the stock holds a Zacks Rank #3 (Hold), indicating expected performance in line with the market. The Retail - Apparel and Shoes sector ranks among the top three industries. Future stock performance will depend on management's outlook and upcoming earnings estimate revisions, with current consensus estimates at $0.30 EPS on $744 million revenue next quarter and $0.35 EPS on $2.91 billion revenue for the fiscal year.

Latest articles

Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

9 June 2026
Regentis Biomaterials shares dipped 2 cents to $1.28 premarket after the company announced European surgeon training for its GelrinC knee implant will begin in Q3, marking a key commercial step but leaving investors waiting for revenue proof as the stock trades far below its $8 IPO price.
IREN Stock Approaches $60 as AI Data-Center Bet Hits Key Point

IREN Stock Approaches $60 as AI Data-Center Bet Hits Key Point

9 June 2026
IREN surged 8.9% to $59.19 and was quoted higher premarket after a bitcoin rebound and renewed focus on its pivot to AI cloud infrastructure, but the stock remains exposed to bitcoin swings, heavy spending, and risks tied to its new 800MW South Australia data center project and major contracts with Nvidia and Microsoft.
AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

9 June 2026
AT&T shares edged up to $22.58 pre-market after reaffirming 2026 guidance and a $45B+ shareholder return plan, providing a cash-flow marker as satellite broadband competition looms; the stock remains pressured by SpaceX risks flagged by Oppenheimer, with second-quarter free cash flow seen at $4.0–$4.5B.
GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

9 June 2026
GSK will buy Nuvalent for $10.6 billion in cash, paying a 40% premium, to boost its oncology pipeline ahead of looming HIV drug patent expiries; Nuvalent shares jumped 38.9% premarket while GSK fell 1.4%, with the deal expected to add to GSK sales and profit from 2027 but dilute earnings per share 2026-2028 if it closes in Q3, and final outcome depends on FDA approvals and regulatory clearance.
Go toTop